WTX 330
Alternative Names: WTX-330Latest Information Update: 02 Jul 2024
At a glance
- Originator Werewolf Therapeutics
- Class Antineoplastics; Immunotherapies; Interleukins
- Mechanism of Action Interleukin 12 replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Non-Hodgkin's lymphoma; Solid tumours
Most Recent Events
- 25 Jun 2024 Efficacy and adverse event data from phase I trial in Non-Hodgkin's lymphoma released by Werewolf Therapeutics
- 23 Apr 2024 Werewolf Therapeutics plans a clinical trials for Solid tumours (multiple tumor types) and Non-Hodgkin's lymphoma (Monotherapy)
- 31 Dec 2023 Werewolf Therapeutics files international application filed under the PCT for certain methods of use with respect to IL-12 INDUKINE molecules and WTX 330, prior to December 2023